[Beta-blockaders and atheroma regression: a necessary evaluation?].
Beta-blockers have been shown to have a beneficial effect especially regarding secondary prevention in coronary patients. The reduction in global mortality is most noticeable with respect to sudden death, which suggests an antiarrhythmic effect, but other non-lethal ischaemic events are also less frequent. The explanation of this observation is certainly multifactorial: some results point to a potential action on the development of atherosclerotic lesions. This justifies experimental and clinical studies of this hypothesis with this pharmacological group of drugs.
IDD (International Drug Development, Paris.
J C
JC
Kerihuel
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001161:Arteriosclerosis / Q000517:prevention & control*; D001809:Blood Viscosity / Q000187:drug effects; D003327:Coronary Disease / Q000517:prevention & control*; D006801:Humans; D008074:Lipoproteins / Q000097:blood / Q000378:metabolism; D011817:Rabbits; D012074:Remission Induction
D000319:Adrenergic beta-Antagonists; D008074:Lipoproteins
Bêtabloqueurs et régression de l'athérome: une évaluation nécessaire?